TOP-5 Price Targets from Analysts on 29.06.26
Reading Time: 3 minutes
Acadia Pharmaceuticals [US0042251084] Citigroup has placed the stock on the list of "Upside Catalysts with 90-Day Focus" - Price Target 35 USD (38% Upside Potential) Analysts see the expected results of the Phase 2 study for Remlifanserin in treating Alzheimer-associated psychosis as a key price driver, with results anticipated between August and October. According to Citigroup, Remlifanserin has the potential to significantly expand Acadia's product portfolio and open up additional growth opportunities for the company in the long term. Should...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
